The week’s winners had cash offers; the losers needed more proof
Takeover offers drove the biggest gains, while failed drug trials, weak retail sales and project funding needs caused heavy falls. Resources dominated company news, but investors rewarded certainty more than ambitious forecasts.
- Mayne Pharma (ASX:MYX) jumped 83.03% after accepting a A$604 million cash takeover.
- Actinogen Medical (ASX:ACW) fell 80.00% after its Alzheimer’s drug missed the main trial goal.
- Adore Beauty (ASX:ABY) dropped 49.06% after cutting earnings guidance and warning about bank terms.
- Nuix (ASX:NXL) and Metro Performance Glass (NZX:MPG) joined a busy takeover market.
- Large mining studies produced strong project values, but most still need permits, funding or buyer commitments.
Add us as a preferred source on Google
Actinogen Medical (ASX:ACW) was the week’s biggest faller, down 80.00% after its Alzheimer’s drug missed the main trial goal. Mayne Pharma (ASX:MYX) delivered the biggest gain, rising 83.03% after agreeing to a A$604 million takeover. Adore Beauty (ASX:ABY) fell 49.06% after cutting its earnings forecast and discussing bank conditions.
Cash offers set the pace
Takeover proposals gave shareholders a clear price and a defined exit. Mayne accepted Gedeon Richter’s A$6.40 offer, a 99.4% premium to its earlier price. The deal still needs regulatory clearance, court approval and the sale of its international business.
Nuix (ASX:NXL) rose 32.52% for the week after giving Haveli five weeks of exclusive access to pursue a A$2.75 cash offer. The board intends to recommend the offer if Haveli completes its checks and signs a binding agreement. Macquarie’s support is important because it owns about 28% of Nuix.
Metro Performance Glass (NZX:MPG) gained 50.25% after Amari Metals offered NZ$1.65 a share. The existing 51% shareholder has agreed to accept. That makes control likely, but Amari still needs enough minority support to remove the company from the NZX and ASX.
Big project values meet large bills
Several mining companies reported large project valuations. WA1 Resources (ASX:WA1) put a A$2.5 billion pre-tax value on its Luni niobium project. Tungsten Mining (ASX:TGN) reported a A$1.57 billion pre-tax value for Watershed.
Those figures are not yet profits. WA1 still needs A$1.069 billion to build Luni. Tungsten Mining needs about A$255 million, binding sales agreements and a final investment decision. Investors sold both shares during the week, with WA1 down 24.69% and Tungsten Mining down 8.11%.
American Rare Earths (ASX:ARR) also reported a US$1.3 billion after-tax value for the first Halleck Creek mine phase. The company still needs permits, recovery testing and US$840 million in initial construction capital. Its shares fell 25.00%.
Biotech falls expose trial and cash concerns
Actinogen’s XanaMIA trial tested whether Xanamem could slow memory loss. The drug did not produce a meaningful result across all 247 patients. A result in older patients was better, but it was not enough to rescue the main test. The company will stop future Phase 3 spending and seek a partner.
Argenica Therapeutics (ASX:AGN) fell 41.67% after the US regulator kept a clinical hold on its stroke drug. It wants a new rat safety study before the next human trial can begin. Nova Minerals (ASX:NVA) dropped 36.84% despite receiving final permits for its Alaska antimony pilot project. The company reported a US$12 million quarterly loss and warned that current resources may not fund a full year of planned work.
Trading updates split the market
TechnologyOne (ASX:TNE) delivered another record year, with annual recurring revenue up 18% to A$652.1 million. Pro Medicus (ASX:PME) won its largest disclosed contract, worth A$128 million over 10 years. These announcements show the value investors place on growing, repeat customer revenue.
Other companies faced more immediate problems. Adore Beauty’s new warehouse caused stock shortages and late deliveries, helping push product revenue down 8% in the first 20 weeks. Webjet (ASX:WJL) reported a statutory loss after weaker online bookings cut underlying earnings by 51%. PEXA (ASX:PXA) warned that proposed fee cuts could reduce revenue by about A$50 million from FY28.
In resources, Gorilla Gold Mines (ASX:GG8) raised A$60 million for its Cosmos acquisition and exploration plans. Many Peaks Minerals (ASX:MPK) raised A$70 million for drilling at Ferké. These raises provide cash for work, but they also add shares and can reduce each existing investor’s percentage ownership.
This Week's Sector Wraps
Compare performance across the market
Bottom Line?
The next phase will test whether proposed takeovers become binding deals and whether large development projects can secure money, permits and sales agreements. Investors should watch the December votes for Global Lithium, the December implementation of oOh!media’s takeover and the 2027 funding milestones across Luni and Watershed.
Questions in the middle?
- Will Haveli turn its A$2.75 Nuix proposal into a binding offer before the five-week exclusive period ends?
- Can Actinogen find a partner after its Alzheimer’s drug missed the main trial goal?
- Will WA1 Resources and Tungsten Mining secure the billions and hundreds of millions needed to build their proposed mines?
Sources
18This wrap draws on announcements from 18 companies. For the full story and each verified source, see the company's own article:
ASX:ABY, ASX:ACW, ASX:AGN, ASX:ARR, ASX:BKT, ASX:GG8, ASX:IDT, ASX:MPK, ASX:MYX, ASX:NVA, ASX:NXL, ASX:PME, ASX:PXA, ASX:TGN, ASX:TNE, ASX:WA1, ASX:WJL, NZX:MPG